Print

Cleveland Biolabs Inc. (CBLI), Incuron, and Roswell Park Cancer Institute Release: Cell Reports Publication Elucidates Role of FACT as Accelerator of Tumor Transformation and Potential Marker and Target of Aggressive Cancers  
7/8/2013 9:58:18 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BUFFALO, N.Y., July 8, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI), Incuron, LLC, a joint venture between CBLI and Bioprocess Capital Ventures, and Roswell Park Cancer Institute (RPCI) today announced the publication of studies describing the Facilitates Chromatin Transcription (FACT) complex as an accelerator of tumor transformation and a potential marker and target for aggressive cancers in Cell Reports, a peer-reviewed journal. FACT is the molecular target for Curaxins, a new class of anti-cancer compounds being developed by Incuron. The reported studies were led by scientists at RPCI.

Help employers find you! Check out all the jobs and post your resume.

//-->